Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.17.
A number of equities research analysts have commented on RGNX shares. Zacks Research upgraded REGENXBIO from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Robert W. Baird lowered their price target on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, August 25th. Wall Street Zen raised REGENXBIO from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 8th. Mizuho assumed coverage on REGENXBIO in a research report on Monday, October 5th. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a report on Friday, September 4th.
Get Our Latest Stock Analysis on REGENXBIO
REGENXBIO Price Performance
Shares of NASDAQ RGNX opened at $6.68 on Friday. The company has a 50 day simple moving average of $8.37 and a 200-day simple moving average of $9.02. The company has a market capitalization of $440.95 million, a P/E ratio of -1.76 and a beta of 1.13. REGENXBIO has a 1 year low of $5.45 and a 1 year high of $16.19.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.08 by $0.35. The firm had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. As a group, research analysts expect that REGENXBIO will post -3.70 EPS for the current year.
Institutional Investors Weigh In On REGENXBIO
Institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc lifted its holdings in shares of REGENXBIO by 60.4% in the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 1,032 shares during the last quarter. Diversified Trust Co boosted its position in shares of REGENXBIO by 15.9% during the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 2,121 shares during the period. Quantbot Technologies LP acquired a new stake in REGENXBIO in the 2nd quarter valued at approximately $51,000. Legal & General Group Plc acquired a new stake in REGENXBIO in the 2nd quarter valued at approximately $56,000. Finally, Entropy Technologies LP acquired a new stake in REGENXBIO in the 1st quarter valued at approximately $87,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.
REGENXBIO Company Profile
REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.
REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.
Featured Stories
- Five stocks we like better than REGENXBIO
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
